Arctic Therapeutics (ATx) is reforming drug development with a focus on genomic data analysis and bioinformatics. By pinpointing disease-related genes and proteins, their innovative process minimizes both risks and costs involved in creating new treatments. Recently securing Series A funding, ATx aims to advance primarily two drugs, notably AT-001, which targets dementia linked to amyloid-induced angiopathy. The CEO, Ívar Hákonarson, highlights its significant potential, allowing for early interventions in high-risk individuals and possibly reversing dementia's progression.
Founded in 2015, Arctic Therapeutics utilizes genomic data and bioinformatics for drug development, potentially reducing costs and time to market.
With the new financing from Series A, ATx plans to advance two frontrunner drugs, particularly AT-001, which targets protein-induced dementia.
CEO Ívar Hákonarson emphasized AT-001's "transformative potential" for earlier interventions and prevention for high-risk individuals, providing hope against dementia.
AT-001 disrupts harmful protein clusters in the brain, aiming to reduce dementia risks and possibly delay its onset or even reverse its progression.
Collection
[
|
...
]